Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347564 | 0.87 | NPSR1 (0.39) | BLMTSHR | |
| SCHEMBL7971343 | 0.78 | CA1 (0.30) | CA1CA2TSHRNT5ECA4 | |
| SCHEMBL5137579 | 0.76 | NPSR1 (0.32) | KDM4E | |
| Hydrochloric Acid SCHEMBL2370581 | 0.69 | — | — | |
| SCHEMBL21822831 | 0.67 | NPSR1 (0.39) | — | |
| SCHEMBL12503609 | 0.65 | NPSR1 (0.42) | — | |
| SCHEMBL23326947 | 0.63 | NPSR1 (0.40) | BLMTSHR | |
| SCHEMBL2141643 | 0.63 | NPSR1 (0.45) | — | |
| SCHEMBL413223 | 0.63 | — | — | |
| SCHEMBL27525935 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101627020-B | HCV inhibiting macrocyclic phenylcarbamates | TIBOTEC PHARM LTD | 2015-06-17 | — | — | CN | disclosed |
| EP-2118091-B1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-04-15 | — | — | EP | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| CN-102858746-B | Novel 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN LA ROCHE | 2014-07-16 | — | — | CN | disclosed |
| CN-102858746-A | Novel 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN LA ROCHE | 2013-01-02 | — | — | CN | disclosed |
| CN-101233131-B | Macrocyclic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD | 2011-06-08 | — | — | CN | disclosed |
| CN-101952289-A | Fused pentacyclic derivatives for use in the treatment of flavivirus infections | GENELABS TECH INC | 2011-01-19 | — | — | CN | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| CN-101627020-A | The macrocyclic phenylcarbamates that suppresses HCV | TIBOTEC PHARM LTD | 2010-01-13 | — | — | CN | disclosed |
| EP-2118091-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | Tibotec Pharmaceuticals (IE) | 2009-11-18 | — | — | EP | disclosed |
| CN-101580535-A | Hepatitis C virus protease inhibitors | TAIGEN BIOTECHNOLOGY CO LTD (CN) | 2009-11-18 | — | — | CN | disclosed |
| CN-101541826-A | Macrocyclic HCV inhibitors and their uses | NOVARTIS AG (CH) | 2009-09-23 | — | — | CN | disclosed |
| WO-2008095999-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| CN-101233131-A | Macrocyclic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD (IE) | 2008-07-30 | — | — | CN | disclosed |
| CN-101189223-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | NUDT1, PNP, SLC28A1 | BLM 1758/4885KDM4E 3794/4885CA1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.